Table 3.
OS and PFS differences in del19 vs. L858R groups
| Drug | PFS | OS | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|||||||||
| Overall | Del19 | L858R | P value | HR | Overall | Del19 | L858R | P value | HR | |
| Gefitinib | 16.2 | 18.3 | 9.5 | 0.1 | 1.76 (1.1-2.8) | 20.1 | 23.7 | 15.9 | 0.01 | 1.83 (1.2-3.7) |
| Erlotinib | 14.5 | 16.8 | 9.7 | 0.3 | 1.37 (0.7-2.5) | NR | NR | 14.3 | 0.003 | * |
| Afatinib | 15.8 | 15.8 | * | * | * | NR | NR | 17.7 | 0.004 | * |
| Osimertinib | 18.4 | 18.4 | NR | 0.2 | NR | NR | NR | * | * | |
PFS: progression-free survival, OS: Overall survival. Please note dacomitinib was given to only 2 patients in the del19 subgroup and hence has been excluded from this analysis.